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Cefquinome is a fourth-generation Cephalosporin approved for use in animals
exclusively. The objective of this study was to explore the relationship of cefquinome
pharmacokinetic/pharmacodynamic (PK/PD) indices with resistance selection of
Staphylococcus aureus ATCC25923 in an in vitro model. Six dosing regiments of
cefquinome at an interval of 24 h for three consecutive times were simulated, resulting
in maximum concentrations (Cmax) from 1/2 to 16MIC and terminal half-lives (t1/2β)
of 3 and 6 h, respectively. The in vitro sensitivity of S. aureus was monitored
by bacterial susceptibility and dynamic time-kill curve experiments over the six
cefquinome concentrations. The correlation between changes in bacterial susceptibility
(MIC72/MIC0) and the percentage of time within mutant selection window versus dosing
interval (TMSW %) was subjected to the Gaussian function and regression analysis. Our
results favored the consensus that time above MIC (T > MIC) was recognized as an
important PK/PD parameter of cephalosporins for antibacterial efficiency. Cefquinome
reached the maximum killing effect when T > MIC% attained approximately 40∼60%.
The subsequent correlation analysis demonstrated that resistant S. aureus ATCC25923
was easy to occur when TMSW% attained an index of about 20% with t1/2β of 3 h after
multiple dosing, and 40% with t1/2β of 6 h after multiple dosing, respectively.
Keywords: cefquinome, Staphylococcus aureus, PK/PD, MPC, in vitro model
INTRODUCTION
Staphylococcus aureus is a major pathogen for animals and humans, which contributes to
a variety of severe infections, including bacteremia, meningitis, endocarditis, skin and wood
infection or other diseases for animals and humans (Archer, 1998; Lowy, 1998; Azizoglu et al.,
2013). More importantly, S. aureus plays an important role in the food contamination by
foodborne pathogens. Food poisoning caused by staphylococcal enterotoxin (SE) is a pressing
worldwide health problem (Tauxe, 2002; Le Loir et al., 2003). In spite of the progress in
antimicrobial therapy, treatment of S. aureus infection has become more and more challenging
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because drug-resistance of S. aureus has increased globally over
the past decade. The methicillin-resistant S. aureus (MRSA)
and vancomycin-resistant S. aureus (VRSA) were particularly
reported and well documented (Harris et al., 2010; Mohammed
Fayaz et al., 2011).
In veterinary medicine, cefquinome (CEQ) has been licensed
in European countries by virtue of its broad antibacterial
spectrums and remarkable antibacterial activities. Despite of
this, the cephalosporins should be in prudent use considering
the escalating antimicrobial resistance. Evidence has showed
that different animal species may harbor the same resistance
determinant and are recognized as possible reservoirs of
antimicrobial-resistant bacteria (Guardabassi et al., 2004). It has
been also observed that cefquinome exerted a selective effect
on blaCTX−M producing Escherichia coli strains (Cavaco et al.,
2008). Therefore, further information concerning the ability of
cefquinome to prevent occurring of resistant strains seems to be
investigated.
Since mutant prevention concentration (MPC) of antibiotics
was first described by Dong et al. (1999), it has been successfully
applied to evaluate the ability of antibiotics that restrict the
selection of resistant strains (Allen et al., 2004; Allen and
Hankins, 2009; Wang et al., 2010; Blondeau et al., 2012) and
optimize the current dosing regimens of antibiotics to slow
the emergence of resistant strains. MPC was taken as the
lowest doubling dilution drug concentration that prevented a
population of 1010 colony forming unit (CFU)/mL or even
more microorganisms from first-step mutation. Zone of the
drug concentrations between minimum inhibitory concentration
(MIC) and MPC was defined as the mutant selection window
(MSW). MPC and MSW concepts, representing the ability of
antibiotics to select resistant strains, have been tested in various
in vitro studies(Allen et al., 2004; Croisier et al., 2004b; Ferran
et al., 2007), in ex vivo pharmacodynamic studies (Bronner et al.,
2002) and in in vivo studies (Croisier et al., 2004a; Cui et al.,
2006). Here, we developed an in vitro kinetic model to investigate
the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) indices of cefquinome with terminal half-lives (t1/2β) of
3 or 6 h and resistance development of S. aureus ATCC25923.
MATERIALS AND METHODS
Antimicrobial Agents, Medium, and
Bacterial Strains
Raw material of cefquinome (purity of 84.1%) was obtained from
Hebei yuanzheng Pharmaceutical Enterprise, Co., Ltd. Mueller-
Hinton broth (MHB) and agar were purchased from Guangzhou
huankai Comapany. S. aureus ATCC 25923 was purchased from
the China Institute of Veterinary Drug Control (Beijing, China).
In Vitro Susceptibility Testing
The MIC of CEQ against S. aureus with an inoculum of 5 × 105
CFU/mL was determined by standard agar dilution method
established by the Clinical and Laboratory Standards Institute
(CLSI).
Measurement of MIC99, Mutant
Prevention Concentration (MPC) and
Selection Index (SI)
The MIC99 was defined as the drug concentration that inhibited
99% of bacteria colony formation. MPC was reckoned as
the lowest cefquinome concentration blocking ≥1010 CFU/mL
inoculants growth. The measurements of MIC99 and MPC
were mainly based on the method reported by Zhao and
Drlica (2002) with slight modification. For MIC99, agar plates
containing a series of cefquinome (concentrations ranging
from 0.5 to 0.164 µg/mL) at 20% per sequential decrease
were prepared. 3 × 107 CFU/mL S. aureus suspension in
logarithmic phase of growth was then subjected to serial
10-fold dilutions with MHB to 3 × 102 CFU/mL bacteria.
Again, 100 µL of each dilution was plated onto the agar
plates containing the series of CEQ concentrations mentioned
above and incubated at 37◦C overnight. Bacterial colonies
that recovered growth in each dilution were counted. Drug
concentrations versus the percentages of colony recovery
were plotted and the interpolation method was adopted to
calculate the cefquinome concentration blocking 99% bacteria
growth.
The determination of MPC was similar to that of MIC99.
Instead, 100 µL of 1010 CFU/mL inoculants was spread on
agar plates containing a series of antimicrobial concentrations.
The lowest antimicrobial concentration preventing bacterial
colony formation at 72 h after incubation was measured as
provisional mutant prevention concentration (MPCpr). A second
determination that utilized linear MPCpr decreases (about 20%
per sequential decrease) was performed. MPC was the lowest
CEQ concentration preventing 100% growth of S. aureus colony.
The calculated ratio of MPC/MIC99 for S. aureus was defined
as selection index (SI) of cefquinome.
In Vitro Dynamic PK/PD Model
Simulation
A previous described dynamic model (Grasso et al., 1978) with
modification was developed in this study. One-compartment
open model with first-order absorption of pharmacokinetics
for cefquinome was simulated. The schematic representation of
in vitro PK/PD model used is depicted in Figure 1. Briefly,
the system was mainly composed of three sealed containers
FIGURE 1 | Scheme of the in vitro dynamic model for bactericidal
kinetics.
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(compartments) and they were connected with peristaltic pumps
in line, each containing sterile MHB and a magnetic stirrer
to ensure adequate mixing. One 500 mL sealed compartment
containing 300 mL MHB, provided with either a bacterial
culture alone (control growth experiments) or a bacterial culture
plus antibiotic (killing/re-growth experiments), acted as the
central chamber. Another 100 mL sealed container charged
with 60 mL of sterile MHB, acted as the absorption chamber,
with desired calculated drug concentrations. The third one
was used to provide fresh MHB. Waste was also collected.
Peristaltic pumps circulated fresh broth to central and absorption
compartments at the desired flow rate. The flow rate of the
pump was set on the basis of the terminal half-life being
simulated. A series of dosage regimens were designed to generate
different CEQ concentration profiles with terminal half-lives
of 3 and 6 h for three consecutive administrations in this
apparatus.
In Vitro PK/PD Model and CEQ Dosing
Regimens
The apparatus ran under 37◦C. The elimination terminal half-
lives of cefquinome reported in the literature varied from 0.5
to 10 h (Limbert et al., 1991; Li et al., 2008; Al-Taher, 2010;
Tohamy, 2011; Yuan et al., 2011; Zonca et al., 2011; Dumka
et al., 2013), therefore, 3 and 6 h were selected in our study.
Peristaltic pumps circulated fresh MHB medium to and from the
central compartment at a flow rate of 15.75 r/min for t1/2β of
3 h or 7.86 r/min for t1/2β of 6 h, respectively. 3 mL bacterial
suspensions (108 CFU/mL) at the logarithmic phase were injected
into the central compartment container. The bacteria were
incubated in the model for 2 h to result in exponentially growing
cultures before addition of cefquinome. Antibiotic doses were
calculated to generate CEQ initial concentrations of 1/2MIC,
MIC, 2MIC, 4MIC, 8MIC, and 16MIC levels, respectively. The
in vitro pharmacokinetics of cefquinome for all doses after three
consecutive administrations with 24 h interval for terminal half-
lives of 3 and 6 h were simulated.
Quantification of Cefquinome in MHB
Samples were collected from the central compartment
immediately before and at 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0,
10.0, 12.0, and 24.0 h after the first and second administration,
and 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 30.0, 36.0, and
48.0 h after the third administration. These samples were stored
at−20◦C until analysis.
1.5 mL of MHB was extracted for the determination of
cefquinome. The concentrations of cefquinome in MHB were
analyzed by high-performance liquid chromatography-MS/MS
(HPLC-MS/MS) with an assay range of 0.005–0.5 µg/mL.
The protein in MHB sample (1 mL) was precipitated by
2 mL acetonitrile, and the supernatant was directly injected
into HPLC-MS/MS after high speed centrifugation. Analysis
of quality control (QC) samples at three levels (0.01, 0.05,
0.2 µg/mL) showed that the recoveries of the method were above
70%; the intra-day and inter-day coefficients of variation were
within 15%. The pharmacokinetic parameters were calculated
by a WinNonlin software (version 5.2.1; Pharsight Corporation,
USA).
In Vitro Time-Kill Experiments and
Susceptibility Testing of S. aureus
To measure the antimicrobial effect of cefquinome with different
terminal half-lives against S. aureus, the colony count and
susceptibility of bacteria in each time point were performed
after treatment. Half of each sample was subjected to time-kill
kinetic assays. Samples (100 µL) in series of 10-fold dilution
with sterile saline (0.9% NaCl) were spread onto Mueller-Hinton
agar to determine the number of total or resistant cells. The
log10 of surviving S. aureus cells (CFU/mL) was plotted against
each time point. The other half of each sample was used for the
susceptibility test. MIC values of bacteria post-exposed in each
time point was conducted using tube dilution method according
to the criteria established by the Clinical Laboratory Standards
Institute [CLSI] (2013).
Pharmacokinetic/Pharmacodynamic
(PK/PD) Integration Analysis
By using the individual pharmacokinetic result from each in vitro
dosage regimen, the following PK/PD parameters were obtained:
ratio of area under the curve of cefquinome concentration versus
time to MIC (AUC0−∞/MIC) or (AUC0−24 h/MIC), ratio of area
under the curve of cefquinome concentration exceeding MIC
to MIC (AUCC > MIC/MIC), time of concentration above MIC
(T > MIC) or MPC (T > MPC), time of concentration within
MPC and MIC (TMSW) or expressed as percentage (TMSW%),
ratio of MIC72 to MICinitial (MIC72/MICinitial).
Gaussian function was used to simulate the correlation of
MIC72 h/MICinitial with TMSW% (percentage of the time during
which cefquinome concentrations were inside the MSW). The
formula was as follows:
y = y0 + A√
2piσ
e−
(x−x0)2
2σ2
where A was the area under curve and upper baseline; x0 was
the minimum value of TMSW% which resulted in the maximum
MIC72 h/MICinitial.
RESULTS
MIC99 and MPC
The MIC99 and MPC of cefquinome against S. aureus ATCC
25923 were 0.4 and 4.096 µg/mL, respectively. So the SI was 10.24
(MPC/MIC99).
In Vitro Simulated Pharmacokinetics
The in vitro simulated time-concentration curves for cefquinome
with terminal half-lives of 3 and 6 h are shown in Figure 2.
This study used time-concentration curves of the unbound
fractions of cefquinome in Mueller-Hinton broth. The maximum
concentrations were approximately equal to 1/2MIC to 16-fold
MIC of cefquinome against S. aureus ATCC 25923 after three
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FIGURE 2 | Concentration-time curves of cefquinome in the in vitro pharmacokinetics model of two terminal half-lives (t1/2β). The horizontal lines
indicate the MPC (4.096 µg/mL) and MIC (0.4 µg/mL) for Staphylococcus aureus ATCC 25923, respectively. (A) t1/2β = 3 h, (B) t1/2β = 6 h.
consecutive administrations. The MPC and MIC levels were also
indicated in the simulated time-concentration curves.
The Bacteria Killing Curves in In Vitro
Models
Time-killing curves of S. aureus ATCC 25923 in the in vitro
model under different dosing regimens are shown in the
following Figure 3. For a t1/2β of 3 h multiple dosages,
bacteriostatic or bactericidal action was observed when
maximum cefquinome concentrations were equal to MIC or
over MIC levels (dosages ranged from 0.672 to 10.767 mg). For
a t1/2β of 6 h multiple dosages, continuous bactericidal action
was observed when maximum cefquinome concentrations were
at 4MIC, 8MIC, 16MIC (dose ranged from 2.691 to 10.767 mg),
and the continuous time of bactericidal action at 16MIC was the
longest among three concentrations.
Frontiers in Microbiology | www.frontiersin.org 4 April 2016 | Volume 7 | Article 466
fmicb-07-00466 April 9, 2016 Time: 14:25 # 5
Li et al. PK/PD Indices of Cefquinome with S. aureus Mutants
FIGURE 3 | Viable counts of S. aureus ATCCC 25923 in time-kill assays with cefquinome in different terminal half-lives (t1/2β) at cefquinome
concentrations from a half to 16-fold the minimum inhibitory concentration (MIC), in comparison with a cefquinome-free control. (A) t1/2β = 3 h, (B)
t1/2β = 6 h.
Loss of Susceptibility to Cefquinome
Compared to drug-free group, loss of susceptibility was
observed in MIC, 2MIC, and 4MIC concentration groups after
administrations, as shown in Figure 4. For multiple dosages with
t1/2β of 3 h, the bacterial MICs after administration increased
to 4.0, 8.0, and 1.0 µg/mL for MIC, 2MIC, and 4MIC groups,
respectively. For multiple dosages with t1/2β of 6 h, the bacterial
MICs after administration increased to 2.0, 4.0, and 0.8 µg/mL
for MIC, and 2MIC, and 4MIC concentration administrations,
respectively. The MIC values did not change through the whole
experiment period in 8MIC and 16MIC administration groups
with two different terminal half-lives.
Correlation of PK/PD Indices with
Resistance Selection
Pharmacokinetic/pharmacodynamic indices, such as
AUC24 h/MIC (where AUC24h is the area under the drug
concentration time curve in a 24 h interval) and time above the
MIC, provide an empirical way to relate antimicrobial dose to
favor the treatment effect of bactericidal agents. Relationships
between PK/PD indices and loss of susceptibility are shown
in Table 1. For cephalosporin, T > MIC was the index most
commonly associated with restricting susceptible cell growth.
When T > MIC attained 17.14 h or T > MIC% attained 24%,
the MIC value of cefquinome against S. aureus increased to
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FIGURE 4 | Typical susceptibility responses of S. aureus ATCCC 25923 observed in the in vitro PK/PD model simulating the pharmacokinetics of
cefquinome with different terminal half-lives (t1/2β). (A) t1/2β = 3 h, (B) t1/2β = 6 h.
16-fold of initial value at 72 h after multiple administrations
in groups with t1/2β of 3 h. Similarly, in groups with t1/2β of
6 h, when T > MIC = 34.28 h or T > MIC% = 48%, the value
of cefquinome MIC increased to eightfold of initial value after
multiple dosages.
Other PK/PD indices also showed correlation with the
selection of resistance (Table 1). When TMSW and TMSW% were
17.14 h and 24%, the MIC increased to 16-fold of initial value
in groups with t1/2β of 3 h after multiple dosages, and the MIC
increased to eightfold of initial value When TMSW and TMSW%
were 34.28 h and 48% with t1/2β of 6 h after multiple dosages,
respectively.
Correlation Analysis of MIC Increase
with TMSW%
According to Gaussian function and regression analysis results,
the bacteria was prone to develop resistance when TMSW%
was about 20% (x0 = 0.2027) in groups with t1/2β of
3 h after multiple dosages (R2 = 0.9989), and TMSW% was
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TABLE 1 | Pharmacokinetic/pharmacodynamic (PK/PD) indices of antimicrobial efficacy and risk of resistance selection amongst Staphylococcus
aureus ATCC 25923 over the complete dosing interval following PK simulations of three consecutive administrations of cefquinome in t1/2β of 3 and 6 h.
t1/2β(h) D (mg)
AUCC>MIC
MIC (h)
AUC24
MIC (h) T > MIC (h) T > MPC (h) TMSW (h) TMSW% T > MIC%
MIC72
MICinitial
3 1/2MIC 0 3.22 0 0 0 0 0 1
MIC 6.41 6.43 8.11 0 8.11 11 11 8
2MIC 25.89 12.89 17.14 0 17.14 24 24 16
4MIC 64.68 25.76 26.13 0 26.13 36 36 2
8MIC 142.34 51.52 35.13 7.81 27.32 38 49 1
16MIC 297.75 103.07 44.14 16.82 27.32 38 61 1
6 1/2MIC 0 5.96 0 0 0 0 0 1
MIC 12.81 11.92 16.21 0 16.21 23 23 4
2MIC 51.77 23.89 34.28 0 34.28 48 48 8
4MIC 129.35 47.73 52.26 0 52.26 73 73 1.5
8MIC 284.68 95.45 70.26 15.63 54.64 76 98 1
16MIC 595.50 190.96 88.28 33.64 54.64 76 123 1
about 40% (x0 = 0.4102) in groups with t1/2β of 6 h after
multiple dosages (R2 = 0.9986), respectively, as shown in
Figure 5. Those results were consistent with the data from
Table 1.
DISCUSSION
Antimicrobial resistance has been a global problem and a great
number of strategies have been proposed to slow the emergence
of resistance (Stratton, 2003; Levy and Marshall, 2004). In
vivo or in vitro PK/PD models have previously been applied
to optimize the dosage regimen of various antibiotics in the
literature (Croisier et al., 2004b; Ferran et al., 2009; Andraud
et al., 2011; Gebru et al., 2012). However, PK/PD model has been
renewably used to investigate relationship of bacterial resistance
with AUC/MIC, Cmax/MIC and T>MIC, recently. In the present
study, we simulated the cefquinome pharmacokinetic profiles
with different terminal half-lives using this dynamic model and
tried to predict the selection of resistant S. aureus with some
indices, such as T > MIC and TMSW%.
It is believed that integration of drug pharmacokinetics,
mutant prevention concentration is helpful in slowing the
emergence of resistance. In this experiment, the MPC and MSW
of cefquinome against S. aureus ATCC25923 were determined.
The SI, ratio of MPC to MIC99, is the ability of a drug to select
resistant mutants (Zhao and Drlica, 2001). In other word, the
bigger the SI is, the easier the drug is to induce resistance. The
SI of cefquinome against S. aureus ATCC25923 was 10.24 in our
study, which suggested that cefquinome could induce S. aureus
resistant mutation easily and effectively.
T > MIC was regarded as a promising predictor for the
efficacy of cephalosporins. Previous pharmacodynamic studies
have addressed separate issues around the relationships between
T > MIC and efficacy for cephalosporins. Craig (1995)
has reviewed the data of efficacy for cephalosporins against
Enterbacteriaceae, streptococci and S. aureus in several animal
infection models and found that the time above MIC required
for a bacteriostatic effect against strains of Enterbacteriaceae,
Streptococci were generally 60–70%, and 40–50% for S. aureus,
respectively. In our study, the value of T > MIC for maximal
killing was 40∼60% for cefquinome against S. aureus reference
strain. In consistent with the widespread idea that antibacterial
efficacy of β-lactams depend on T > MIC, the effect of
cefquinome against S. aureus in our study exhibited similar
correlation. As observed in Figure 3, killing curves of S. aureus
exposed to each dose of cefquinome showed the typical pattern
of time-dependent bactericidal action. The similar observation
was also reported for other β-lactam drugs in previous studies
(Lindecrona et al., 2000; Burgess and Hall, 2004). Considering
that the T > MIC was one of the most important parameters
for optimal dosage regimen, T > MIC was selected as a
parameter to evaluate resistant mutation in this article. In
the present study, the values of T > MIC ranging from
8.11 to 17.14 h were dangerous zones for inducing resistant
mutation in groups with t1/2β of 3 h after multiple dosages,
and values ranging from 16.21 to 34.28 h were dangerous
zones for inducing resistant mutation in groups with t1/2β of
6 h multiple dosages. Compared these values with previously
reported study data that T > MIC value ranged from 42 to
54 h for cefquinome in dairy cows (Zonca et al., 2011), the
prevention of selecting resistant S. aureus strains seems to
be achieved by the present dosage regimens approved by the
European Medicines Agency (EMA) for the treatment of dairy
cow mastitis.
TMSW is another important parameter used for evaluating
resistant mutation. A previous study conducted in a rabbit
lung infection model with Streptococcus pneumonia showed that
the selection of resistant bacteria occurred systematically when
concentrations of gatifloxacin were within the MSW (TMSW)
for more than 45% of the treatment duration (Croisier et al.,
2004b). Another experiment in rabbits infected by S. aureus also
showed that time in the MSW > 33% was preferable to select
mutants (Cui et al., 2006). When the abilities of the indices
TMSW, AUC24 h/MIC, Cmax/MIC to predict the selection of
resistant bacteria were compared, only TMSW appeared to be
a good predictor of the prevention of resistance (Ferran et al.,
2009). In this study, TMSW was also used to predict selection of
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FIGURE 5 | Relationship between the TMSW% and MIC72/MIC0 for S. aureus ATCC 25293 exposed to cefquinome in the in vitro model with two
terminal half-lives (t1/2β). (A) t1/2β = 3 h, (B) t1/2β = 6 h.
resistant S. aureus against cefquinome. It was clearly determined
that when TMSW was above 36% in groups with t1/2β of 3 h
after multiple dosages or above 73% in groups with t1/2β of 6 h
after multiple dosages, cefquinome could restrict the resistant
mutation.
In the present investigation, the bacterial resistant mutation
was affected by different terminal half-lives and dosages. Within
the group of the same terminal half-life (3 or 6 h), the bacterial
resistant mutation happened under the condition of relative low
dosage (maximum concentrations were 2MIC and 4MIC). When
the maximum concentration was over 8MIC, resistant mutation
was prevented. In the same dosages (maximum concentration
was 2MIC or 4MIC), the MIC72 h increased from 8- to 16-fold in
groups with t1/2β of 3 h after multiple dosages and increased from
4- to 8-fold in groups with t1/2β of 6 h after multiple dosages,
respectively. Those results suggested that the bacterial resistant
mutation might happen at a low concentration. In high dosages
or long terminal half-lives, the drug concentrations might exceed
the MPC value, the upper boundary of MSW, and the resistant
mutation could be inhibited. The conclusion from this study was
consistent with other similar studies (Cui et al., 2006; Ferran et al.,
2009; Zhu et al., 2012).
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The limitation of the study was that only one reference
strain was used to simulate the efficacy of cefquinome in
this in vitro model; however, the multi-resistance is becoming
an urgent trend all over the world. It may be reasonable
that more clinical isolates of S. aureus could be used for
further study. Firsov et al. (2008) used two methicillin-
resistant strains of S. aureus, ATCC 6538 and ATCC 43300,
to study the enrichment of ciprofloxacin resistant mutation in
an in vitro dynamic model. Liang et al. (2011), chose three
clinical isolates of S. aureus, SA99, RN450 and RN450-A1,
to analyze the enrichment of levofloxacin resistant mutation
with in vitro dynamic model. From the results obtained in
the dynamic model, more clinical isolates could be used to
study resistant mutation easily based on the substantial method.
Moreover, to our knowledge, evaluation of antimicrobial activity
for cefquinome with different terminal half-lives is scarce.
Considering the fact that cefquinome is the time-dependent
drug, it is positive to study the correlation resistant mutation
with different terminal half-life conditions. Another limitation of
the current study was the absence of resistance mechanisms of
S. aureus observed in vitro. Therefore, the pattern of S. aureus
resistant to cefquinome, such as production of β-lactamases,
alteration of drug targets, porin-mediated resistance, and/or
eﬄux-mediated resistance, needs confirmation in the further
study.
CONCLUSION
The present study of resistant mutation with S aureus ATCC
25923 exposed to cefquinome with two different terminal half-
lives in in vitro dynamic models supports the MSW hypothesis
and provides some useful parameters to predict the resistant
mutation, especially T > MIC and TMSW%. Further study will
concentrate on more clinical isolates which could be used for
verification of these results and resistance patterns of S. aureus
resistant to cefquinome.
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